Why BPC-157 for Gut Conditions?
BPC-157 (Body Protective Compound-157) is a 15-amino acid peptide fragment derived from a protein in human gastric juice. Unlike most peptides that must be injected to survive digestion, BPC-157 is remarkably stable in gastric acid — it appears to have evolved specifically to support gut integrity.
This stability makes oral BPC-157 capsules an effective delivery route for gut conditions, where the peptide can act locally on intestinal tissue during transit rather than requiring systemic absorption.
Conditions Commonly Treated
Irritable Bowel Syndrome (IBS)
Reduces intestinal hypersensitivity and modulates gut motility. Many patients report significant reduction in bloating, cramping, and alternating bowel habits.
Leaky Gut / Intestinal Permeability
Supports tight junction integrity and mucosal barrier repair — the primary mechanism behind 'leaky gut.' Reduces inflammatory signaling through the gut wall.
GERD / Acid Reflux
Protects the esophageal and gastric mucosa, reduces inflammation, and may support lower esophageal sphincter function in preclinical models.
Inflammatory Bowel Disease
Used adjunctively for Crohn's and ulcerative colitis under physician supervision. Anti-inflammatory and mucosal healing effects are supported by preclinical IBD models.
Post-Antibiotic Gut Recovery
Supports restoration of gut lining integrity and reduction of inflammation following antibiotic disruption.
Post-Surgical GI Recovery
Accelerates healing of GI tissue following abdominal surgery, colonoscopy trauma, or anastomosis healing.
Oral vs. Injectable BPC-157 for Gut
Oral Capsules (preferred for gut)
Acts locally on GI tract during transit. Stable in gastric acid. Easiest administration. Standard dose: 250–500mcg, 1–2x daily with food. Best for upper and lower GI conditions.
Subcutaneous Injection
Systemic distribution. Better if gut issues are concurrent with injury, nerve, or inflammatory conditions elsewhere. Some patients with severe gut conditions use both routes under physician guidance.
Important note on clinical evidence
Most BPC-157 gut research is from animal models. Human clinical trial data is limited. BPC-157 is not FDA-approved for any GI condition. Patients with diagnosed IBD, Crohn's, or ulcerative colitis should coordinate care with their gastroenterologist before starting peptide therapy. BPC-157 is not a replacement for established GI treatments.